Hemostasis is a physiological processes, which maintains fluidity of blood by preventing blood loss from body. Hemostasis is characterized by clot formation by activating the natural coagulation cascade. However, in cases of major surgeries and trauma, the blood loss is excessive and cannot be stopped through natural healing process. Thus, hemostats and tissue sealing agents aid in such situations by minimizing the blood loss and helps in healing the injury. Hemostats and tissue sealing agents are increasingly being used, as excessive bleeding during surgical procedures can lead to high risk. Moreover, excessive bleeding can also result in postoperative complications that include prolonged surgical procedures and insufficient blood in the body. According to In-Patient Epidemiology, a statistical survey conducted by Department of Surgery, Division of Acute Care and Trauma Surgery, New York University 2012, blood loss accounts for up to 31% of deaths in victims of trauma and catastrophic accident patients in the U.S. Therefore, prevention of such occurrences is important for positive patient outcomes and success of surgical procedures. Thus, topical hemostats in terms of mechanical hemostats, active hemostats, and Flowable hemostats, that are solutions topically applied directly on the bleeding site as well as natural and synthetic tissue sealants act as adjunct to natural hemostasis procedure and are applied locally to control blood loss.


Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1567


Rising number of surgical procedures coupled with increasing trauma cases to foster global hemostasis & tissue sealing agents market

Factors such as increasing number of surgical procedures as well as rising number of road accidents are expected to significantly contribute to growth of the hemostasis and tissue sealing agents market. For instance, according to Health and Social Care Information Centre (HSCIC), surgery is one of the most important treatments offered by NHS care in the U.K., and accounted for 4.7 million admissions across multiple sectors in 2013-14. The data also suggests that the number of surgical procedures has increased by 27% between 2004 and 2014. According to Centers of Disease Control and Prevention (CDC), around 200,000 deaths were encountered in 2014, due to trauma injuries in the U.S. Increasing incidence of road accidents has led to traumatic sport injuries is a major factor fueling demand for hemostats, thereby driving the market growth. According to the World Health Organization 2016, over 50% affected in road traffic accidents were admitted in the hospitals and underwent trauma surgeries. Hemostats are used in trauma surgeries and also in various conventional surgeries such as hernia repair surgery, orthopedic, open heart and cardiovascular surgeries, and neurosurgery that involve significant blood loss, due to larger size incisions made on the body of the patient. According to the annual report of American Joint Replacement Registry (AJRR), 2016, a total of 427,181 procedures were reported for joint replacement surgeries. However, lack of favorable reimbursement policies for failure of hemostats in blood loss control as well as increasing cost of surgical procedures is expected to hinder the market growth.

Market Dynamics

Hemostats and tissue sealants are used in a wide range of medical applications that include hernia fixation surgery, orthopedic surgery, spinal injury, trauma or accident wound closure, ophthalmic injuries or replacements, burns, neurosurgeries, urological disorders, and other chronic conditions to control excessive bleeding. Thus, increasing number of surgical procedures is expected to be a major factor augmenting growth of the global hemostasis and tissue sealing agents market. For instance, according to the Wound Management Innovation Center, 2015, wounds are estimated to affect over 433,000 people in Australia and the economic burden is estimated to be around US$ 2.85 billion per year. Moreover, according to The World Bank in 2012, the number of surgical procedures performed per 100,000 population were accounted to be 4,511 globally. However, lack of reimbursement for these agents and products could hinder the market growth.

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/1567

Key players operating the global hemostasis & tissue sealing agents market include Cryolife, Inc. Baxter International, Inc., Ethicon LLC, Integra Lifesciences Corporation, Becton, Dickinson & Company, Cohera Medical, Inc., Pfizer, Inc., Medtronic plc, B. Braun Melsungen AG, MIL Laboratories Pvt. Ltd, Advanced Medical Solutions Group Plc, and others.



About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]